Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of Blood, Blood Forming Organs and Immunologic DisordersDRG 811-red-blood-cell-disorders-with-mcc
    Ask Trek AI about this page

    Red Blood Cell Disorders with MCC: Inpatient Reimbursement Overview

    DRG 811 encompasses inpatient admissions for red blood cell disorders with a Major Complication or Comorbidity, capturing cases with significant severity or resource needs. This classification matters for inpatient reimbursement because presence of a Major Complication or Comorbidity increases payment weight under the Diagnosis-Related Group system.

    Customize your policy alerts

    Sign up for drg 811 policy alerts

    Get alerted when payer policies referencing 811 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 811 Overview

    DRG 811 covers inpatient stays for red blood cell disorders with a Major Complication or Comorbidity, including severe hemolytic anemias, refractory anemia requiring transfusion support, and other acute or complicated hematologic presentations tied to red blood cell pathology. This Diagnosis-Related Group is used to classify hospitalizations where the presence of a Major Complication or Comorbidity drives higher resource use and longer length of stay. It matters for Medicare payment because assignment to DRG 811 typically yields higher reimbursement relative to lower-severity red blood cell disorder groups, reflecting the increased costs of care. Accurate clinical documentation and coding determine whether an encounter qualifies for this higher-severity Diagnosis-Related Group.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute transfusion and hemostatic intervention trials: studies that evaluate timing, dosing strategies, and protocols for red blood cell transfusion and associated hemostatic therapies in hospitalized patients with severe anemia or acute hemolysis complicated by major comorbidities. These trials typically enroll inpatients with critical drops in hemoglobin, transfusion-dependent bleeding, or hemolytic events requiring urgent stabilization, and compare restrictive versus liberal transfusion thresholds, rapid crossmatching technologies, or adjunctive therapies to control bleeding. Results inform clinicians on safe, effective acute-management pathways and help payers assess resource utilization and short-term cost drivers tied to transfusion frequency and length of stay.
    • Comparative effectiveness and guideline-driven management studies in chronic and complex red blood cell disorders: pragmatic trials and observational comparative studies that assess different care pathways (specialist-led inpatient management, transfusion protocols, erythropoiesis-stimulating strategies, or combined inpatient–outpatient coordination) for patients hospitalized with chronic anemias complicated by major complications (for example, sickle cell crises with organ dysfunction or transfusion-refractory anemia with severe comorbidity). These studies focus on heterogeneous inpatient populations with multiple comorbidities and aim to measure outcomes such as in-hospital mortality, complication rates, readmissions, and cumulative transfusion exposure. Findings are directly relevant to providers optimizing care plans and to payers interested in reducing complications, readmissions, and cumulative cost from serial inpatient admissions.
    • Post-discharge outcomes, readmission prevention, and transitions-of-care research: cohort studies and interventional trials that evaluate discharge planning, outpatient transfusion programs, home-monitoring, or care-coordination interventions for patients recently hospitalized with red blood cell disorders and major complications. These studies enroll patients at the point of discharge or within the early post-discharge window to test strategies that reduce early readmission for recurrent anemia, hemolysis, or transfusion-related complications and to monitor long-term functional outcomes and quality of life. Evidence from this research guides hospital discharge policies, outpatient follow-up requirements, and payer decisions about coverage for transitional services that can lower readmission rates and overall episode costs.

    Related Codes

    799-SPLENIC-PROCEDURES-WITH-MCC

    Splenic Procedures with MCC: Inpatient Reimbursement Overview

    800-SPLENIC-PROCEDURES-WITH-CC

    Splenic Procedures with CC: Inpatient Reimbursement Overview

    801-SPLENIC-PROCEDURES-WITHOUT-CC-MCC

    Splenic Procedures without CC/MCC: Inpatient Reimbursement Overview

    802-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs with MCC: Inpatient Reimbursement Overview

    803-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-CC

    Other O.R. Procedures of the Blood and Blood Forming Organs with CC: Inpatient Reimbursement Overview

    804-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITHOUT-CC-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs without CC/MCC: Inpatient Reimbursement Overview

    808-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    809-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-CC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    810-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITHOUT-CC-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    812-RED-BLOOD-CELL-DISORDERS-WITHOUT-MCC

    Red Blood Cell Disorders without MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 14

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.